Ionis Pharmaceuticals ( NASDAQ:IONS – Get Free Report ) ‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Thursday, MarketBeat.com reports. They presently have a $100.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 124.88% from the company’s current price.
A number of other analysts have also commented on IONS. Canaccord Genuity Group reduced their price target on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, September 8th. The Goldman Sachs Group reduced their price target on shares of Ionis Pharmaceuticals from $69.00 to $56.00 and set a “neutral” rating for the company in a research note on Tuesday, September 8th. Jefferies Financial Group dropped their price objective on shares of Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, July 9th. Citigroup dropped their price objective on shares of Ionis Pharmaceuticals from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, Barclays dropped th...